Actor Eric Dane pushes for ALS research: Not ‘the end of my story’
Actor Eric Dane is teaming up with Target ALS on a campaign to raise $500,000 by Dec. 31 to…
Articles by Margarida Maia, PhD
FDA authorizes new Phase 3 clinical trial of PrimeC for ALS
The U.S. Food and Drug Administration (FDA) has authorized Neurosense Therapeutics to begin a pivotal Phase 3 trial of…
Researchers find way to make diagnosis of ALS more accurate
Combining two blood biomarkers may make the diagnosis of amyotrophic lateral sclerosis (ALS) more accurate and help predict how…
Cost of ALS care in US in first year tops $47K for Medicare users
People with amyotrophic lateral sclerosis (ALS) spend upward of $47,000 on medical care during the first year after their…
Head trauma may be an early sign, not a cause of ALS: Study
People with a history of traumatic brain injury (TBI) have a nearly three times higher risk of developing amyotrophic…
Immune checkpoints may predict ALS severity, progression
Immune checkpoint proteins — proteins that help regulate immune response — were elevated on T-cells and in the blood of…
New trial to test effectiveness of COYA 302 to slow ALS progression
Coya Therapeutics has launched a Phase 2 clinical trial of COYA 302 — an experimental therapy combining the signaling…
In trial, Neuronata-R benefits ALS patients with slower progression
In adults with amyotrophic lateral sclerosis (ALS) who have slower disease progression, the stem cell therapy Neuronata-R (lenzumestrocel) — conditionally…
New analysis shows Radicava ORS slows ALS decline
A retrospective analysis using data from two clinical studies and their extension periods showed that Radicava ORS, an oral formulation…
Repurposed vet drug helps ALS patients live longer: Study
A veterinary medication repurposed as a treatment for amyotrophic lateral sclerosis (ALS) helped patients live longer and slowed disease…